Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma

Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study

“…In a Japanese cohort, Miyake et al (11) found that eTS was an independent predictor of better OS in patients treated with 1st line sunitinib or sorafenib. Even in 2nd line treatments with axitinib, sunitinib, everolimus, temsirolimus, and sorafenib, eTS was a significant predictive factor of OS (13). In this study, treatment with axitinib resulted in earlier shrinkage than with other agents, thereby supporting the present results on axitinib.…”

“…Rini et al (12) demonstrated that patients with eTS ≤-0.1 and administered axitinib were treatable for longer than 18 months and also had superior OS to those with eTS >-0.1. Similarly, Grünwald et al (13) reported that an eTS cut-off-0.1 is a strong predictor of OS and PFS in a large scale (n=4,334) study. In a Japanese cohort, Miyake et al (11) found that eTS was an independent predictor of better OS in patients treated with 1st line sunitinib or sorafenib.…”

“…However, a similar study in the MTT era was not conducted in Japan. Furthermore, a novel concept, 'early tumor shrinkage (eTS)', was reported to predict survival under MTT (11)(12)(13). In the present study focused on eTS, we reviewed our MTT experience and identified predicting factors of mRCC in the MTT era before the introduction of 2nd generation immunotherapy era.…”

Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer

“…AGC patients who showed ETS was similar to results for mCRC patients treated with first-line chemotherapy plus EGFR inhibitors [14]. In other cancers treated by tyrosine kinase inhibitors (such as renal cell adenocarcinoma), ETS also identified patients who were likely to benefit from treatment with antitumor agents [15]. Grünwald et al reported that patients who reached 10% ETS had significantly longer OS (HR: 0.615, P \ 0.0001, median 28.5 vs. 16.0 months) and PFS (HR: 0.628, P \ 0.0001, median 10.5 vs. 5.3 months) than did patients without ETS (Cox proportional hazards models).…”

The significance of apparent diffusion coefficient of MRI in early therapeutic response assessment in patients who undergo systemic treatment of renal cell carcinoma

“…Проте типові критерії Response Evaluation Criteria In Solid Tumors (RECIST), які на даний момент застосовуються для оцінки ступеня терапевтичної відповіді при системному лікуванні НКР, не дозволяють повноцінно характеризувати глибинні зміни, що відбуваються в тканинах пухлини під дією таргетних агентів, а отже, із достатньою точністю характеризувати чи передбачати ефект такої терапії [2,3]. Недосконалість вищезгаданої системи неодноразово визнана багатьма клініцистами [4][5][6][7]. Оновлена версія критеріїв RECIST (версія 1.1) продемонструвала відсутність різниці у передбаченні TTP у хворих на НКР, порівняно з попереднім варіантом (версія 1.0) [5,6].…”